An interventional study of Arterial bypass grafting in Critical Lower Limb Ischemia, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Atherosclerosis with a site in Russian Federation — 5 open to participants now, 5 under way, none of them phase 3. Atherosclerosis · Russian Federation.
Among the 35 studies in Atherosclerosis with a site in Russian Federation, this one is the 14th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 32nd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →5 of the 35 studies in Atherosclerosis with a site in Russian Federation are open now. Recruiting first, the newest first:
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Sites in Russian Federation
Ages 50–80
Center for Strategic Planning, of the Federal Medical and Biological Agency · Sites in Russian Federation
Ages 18+
Meshalkin Research Institute of Pathology of Circulation · Sites in Russian Federation
Ages 45–80
Russian Cardiology Research and Production Center · Sites in Russian Federation
Ages 7–80
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 200 across the 27 interventional studies, 1,000 across the 8 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Ryazan State Medical University has 2 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Atherosclerosis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will examine the results of the use of biological materials (allogeneic arterial grafts, allogeneic venous graft, autologous vein, biological bovine decellularized graft) as a bypass grafts for reconstructive interventions in patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease in the short-term and long-term postoperative periods. Histological analysis of allogeneic grafts will be carried out at various time points of graft preservation with a Roswell Park Memorial Institute 1640 cell medicum with 400mcg/ml gentamicin and 20mcg/ml fluconazole at a temperature of +4C.
The physical properties of allogeneic grafts from postmortem donors (tensile and tear strength) will be evaluated at various conservation time periods (1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks). Markers of endothelial dysfunction (IL-6, endothelin-1, 6-keto-prostaglandin F1alfa, eNOS) will be evaluated in patients with critical ischemia who undergo bypass procedures with arterial and venous allografts at various time points (before surgery, 7 days, 1 month, 3 months, 6 months, 1 year after).
The study will include 200 patients of similar age, gender, and ethnicity, who will be divided into four groups:
Group I: 50 patients who undergo arterial bypass procedures using autologous venous graft derived from great saphenous vein; Group II: 50 patients who undergo arterial bypass procedures using allogeneic venous grafts; Group III: 50 patients who undergo arterial bypass procedures using allogeneic arterial grafts; Group IV: 50 patients using biological bovine decellularized grafts.
Patients will be monitored for 2 years: at inclusion, and 1, 3, 6, 12, 18, and 24 months after bypass procedures.
The primary endpoint of the study will be mortality, i.e. death of the patient from any cause. Secondary endpoints of the study will be graft thrombosis and cardiovascular events such as myocardial infarction, acute coronary syndrome, transient ischemic attack, and stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft
Procedure: Arterial bypass grafting
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft
Procedure: Arterial bypass grafting
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft
Procedure: Arterial bypass grafting
Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft
Procedure: Arterial bypass grafting
Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
Number of Participants with lethal outcomes
The primary outcome measure is mortality rate
Time frame: 24 months
Number of Participants with Graft thrombosis
The secondary outcome measure is graft thrombosis
Time frame: 24 months
Myocardial infarction
The secondary outcome measure is myocardial infarction
Time frame: 1, 3, 6, 12, 18, and 24 months
Number of Participants with Acute coronary syndrome
The secondary outcome measure is acute coronary syndrome
Time frame: 24 months
Number of Participants with Stroke or transient ischemic attack
The secondary outcome measure is stroke or transient ischemic attack
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2025, 48 months after the start.
Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 48 months is above that.
Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ryazan State Medical University